Marjolijn Duijvestein

Marjolijn Duijvestein

Auto-generated profile, based on publicly available information

Marjolijn Duijvestein

Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2020 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
ASAZUCENA SALAS
AZUCENA SALAS
CHCristian Hernandez-Rocha
Cristian Hernandez-Rocha
MDMarjolijn Duijvestein
Marjolijn Duijvestein
WFWilliam Faubion
William Faubion
DMDermot McGovern
Dermot McGovern
NCNiels Vande Casteele
Niels Vande Casteele

14 February 2022 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
BVBram Verstockt
Bram Verstockt
SVStefania Vetrano
Stefania Vetrano
ASAZUCENA SALAS
AZUCENA SALAS
SNShadi Nayeri
Shadi Nayeri
MDMarjolijn Duijvestein
Marjolijn Duijvestein
SVSeverine Vermeire
Severine Vermeire

26 May 2022 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
TSTessa Straatmijer
Tessa Straatmijer
VBVince B.C. Biemans
Vince B.C. Biemans
MVMarijn Visschedijk
Marijn Visschedijk
FHFrank Hoentjen
Frank Hoentjen
AVAnnemarie de Vries
Annemarie de Vries
BMBart Muskens
Bart Muskens
Clinicians face difficulty in when and in what order to position biologics and Janus kinase inhibitors in patients with anti-tumor necrosis factor-alpha (TNF) refractory ulcerative colitis (UC). We aimed to compare the effectiveness and safety of vedolizumab and tofacitinib in anti-TNF-exposed patients with UC in our prospective nationwide Initiative on Crohn and Colitis Registry. Patients with UC who failed anti-TNF treatment and initiated vedolizumab or tofacitinib treatment were identified in the Initiative on Crohn and Colitis Registry in the Netherlands. We selected patients with both clinical as well as biochemical or endoscopic disease activity at initiation of therapy. Patients previously treated with vedolizumab or tofacitinib were excluded. Corticosteroid-free clinical remission (Simple Clinical Colitis Activity Index ≤2), biochemical remission (C-reactive protein ≤5 mg/L or fecal calprotectin ≤250 μg/g), and safety outcomes were compared after 52 weeks of treatment. Inverse propensity score-weighted comparison was used to adjust for confounding and selection bias. Overall, 83 vedolizumab- and 65 tofacitinib-treated patients were included. Propensity score-weighted analysis showed that tofacitinib-treated patients were more likely to achieve corticosteroid-free clinical remission and biochemical remission at weeks 12, 24, and 52 compared with vedolizumab-treated patients (odds ratio [OR], 6.33; 95% confidence interval [CI], 3.81-10.50; P < .01; OR, 3.02; 95% CI, 1.89-4.84; P < .01; and OR, 1.86; 95% CI, 1.15-2.99; P = .01; and OR, 3.27; 95% CI, 1.96-5.45; P < .01; OR, 1.87; 95% CI, 1.14-3.07; P = .01; and OR, 1.81; 95% CI, 1.06-3.09; P = .03, respectively). There was no difference in infection rate or severe adverse events. Tofacitinib was associated with superior effectiveness outcomes compared with vedolizumab in anti-TNF-experienced patients with UC along with comparable safety outcomes.

30 March 2021 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
VJVincent Joustra
Vincent Joustra
MDMarjolijn Duijvestein
Marjolijn Duijvestein
AMAart Mookhoek
Aart Mookhoek
WBWillem Bemelman
Willem Bemelman
CBChristianne Buskens
Christianne Buskens
GDGeert R. D’Haens
Geert R. D’Haens
Prediction of endoscopic postoperative recurrence (POR) and prophylactic treatment based on clinical risk profile have thus far been inconclusive. This study aimed to examine the association between clinical risk profile and the development of endoscopic POR in a Crohn’s disease population without postoperative treatment and to identify individual risk factors of endoscopic POR. Medical records of 142 patients with Crohn’s disease during follow-up after ileocecal or ileocolonic resection without prophylactic treatment at 3 referral centers were reviewed. Endoscopic POR was defined as a modified Rutgeerts score ≥i2b. Clinical risk profiles were distilled from current guidelines. Both uni- and multivariate logistic regression analysis were used to assess the relationship between risk profiles and endoscopic POR. Endoscopic POR was observed in 68 out of 142 (47.9%) patients. Active smoking postsurgery (odds ratio [OR], 3.01; 95% confidence interval [CI], 1.24-7.34; P = 0.02), a Montreal classification of A3 (OR, 3.05; 95% CI, 1.07-8.69; P = 0.04), and previous bowel resections (OR, 2.58; 95% CI, 1.07-6.22; P = 0.03) were significantly associated with endoscopic POR. No significant association was observed between endoscopic POR and any guideline defined as a high-/low-risk profile. However, patients with a combination of any 3 or more European Crohns & Colitis Organisation– (OR, 4.87; 95% CI, 1.30-18.29; P = 0.02) or British Society of Gastroenterology–defined (OR 3.16; 95% CI, 1.05-9.49; P = 0.04) risk factors showed increased odds of developing endoscopic POR. Our results suggest that patients with a combination of any 3 or more European Crohns & Colitis Organisation– or British Society of Gastroenterology–defined risk factors would probably benefit from immediate prophylactic treatment.

16 October 2020 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
SGSara van Gennep
Sara van Gennep
NBNanne De Boer
Nanne De Boer
MGMarieke E. Gielen
Marieke E. Gielen
SRSvend T. Rietdijk
Svend T. Rietdijk
KGKrisztina B. Gecse
Krisztina B. Gecse
ABAngela G. E. M. de Boer
Angela G. E. M. de Boer
Background Work-related aspects are important determinants of health for inflammatory bowel disease (IBD) patients. Aims We aimed to describe quality of working life (QWL) in IBD patients and to assess variables that are associated with QWL. Methods Employed IBD patients of two tertiary and two secondary referral hospitals were included. QWL (range 0–100) was measured using the Quality of Working Life Questionnaire (QWLQ). Work productivity (WP), fatigue, and health-related quality of life (HRQL) were assessed using the Work Productivity and Activity Impairment questionnaire, Multidimensional Fatigue Inventory, and Short Inflammatory Bowel Disease Questionnaire, respectively. Active disease was defined as a score > 4 for the patient-reported Harvey–Bradshaw index in Crohn’s disease (CD) or Simple Clinical Colitis Activity Index in ulcerative colitis patients. Results In total, 510 IBD patients were included (59% female, 53% CD, mean age 43 (SD 12) years). The mean QWLQ score was 78 (SD 11). The lowest subscore (54 (SD 26)) was observed for “problems due to the health situation”: 63% reported fatigue-related problems at work, 48% agreed being hampered at work, 46% had limited confidence in their body, and 48% felt insecure about the future due to their health situation. Intermediate/strong associations were found between QWL and fatigue (r = − 0.543, p < 0.001), HRQL (r = 0.527, p < 0.001), WP loss (r = − 0.453, p < 0.001) and disease activity (r = − 0.331, p < 0.001). Independent predictors of impaired QWL in hierarchical regression analyses were fatigue (B = − 0.204, p < 0.001), WP loss (B = − 0.070, p < 0.001), and impaired HRQL (B = 0.248, p = 0.001). Conclusions IBD-related problems at work negatively influence QWL. Fatigue, reduced HRQL, and WP loss were independent predictors of impaired QWL in IBD.

1 August 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
CMChristopher Ma
Christopher Ma
KGKrisztina B. Gecse
Krisztina B. Gecse
MDMarjolijn Duijvestein
Marjolijn Duijvestein
WSWilliam J. Sandborn
William J. Sandborn
GZGuangyong Zou
Guangyong Zou
GDGeert R. D’hAens
Geert R. D’hAens
Endoscopic evaluation for postoperative recurrence of Crohn's disease (CD) is routinely integrated into clinical practice. The Rutgeerts score (RS) was developed to grade the severity of endoscopic postoperative CD recurrence and has been integrated into clinical practice guidelines and utilized as an endpoint in interventional trials.1,2 However, the operating properties of the RS have not been fully assessed. Furthermore, the RS i2 grade groups purely anastomotic ulcerations with those in the neoterminal ileum, whereas the modified Endoscopic Postoperative Recurrence Score (mEPRS) distinguishes lesions limited to the ileocolic anastomosis (i2a) from those in the neoterminal ileum (i2b). Accurate characterization of endoscopic recurrence is an important determinant for initiating postoperative medical therapy. Therefore, variability in endoscopic scoring may result in inappropriate therapeutic decisions.3 We evaluated the reliability of endoscopic assessment of postoperative CD recurrence among independent blinded central readers.